Literature DB >> 31262761

Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae.

Matthew C Canver1,2, Michael J Satlin1,3, Lars F Westblade1,2, Barry N Kreiswirth4, Liang Chen4, Amy Robertson1, Kathy Fauntleroy1, Marisa La Spina1, Katrina Callan1, Stephen G Jenkins5,2.   

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) strains are an urgent public health threat. We evaluated the in vitro activities of 19 antimicrobial agents, including imipenem-relebactam, against (i) 106 CRE bloodstream isolates that primarily expressed Klebsiella pneumoniae carbapenemase (KPC) and (ii) 20 OXA-48-like-expressing CRE isolates. Ninety-five percent of CRE bloodstream isolates were susceptible to imipenem-relebactam. In contrast to their comparable activities against KPC-producing CRE strains, ceftazidime-avibactam was more active in vitro against OXA-48-like CRE strains than was imipenem-relebactam (90% susceptible versus 15% susceptible).
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  carbapenem-resistant Enterobacteriaceaezzm321990; ceftazidime-avibactam; imipenem-relebactam

Year:  2019        PMID： 31262761      PMCID： PMC6709495          DOI： 10.1128/AAC.00672-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Authors:  George G Zhanel; Courtney K Lawrence; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Michael Zhanel; Philippe R S Lagacé-Wiens; Andrew Walkty; Andrew Denisuik; Alyssa Golden; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

2.  Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.

Authors:  Michael J Satlin; Liang Chen; Gopi Patel; Angela Gomez-Simmonds; Gregory Weston; Angela C Kim; Susan K Seo; Marnie E Rosenthal; Steven J Sperber; Stephen G Jenkins; Camille L Hamula; Anne-Catrin Uhlemann; Michael H Levi; Bettina C Fries; Yi-Wei Tang; Stefan Juretschko; Albert D Rojtman; Tao Hong; Barun Mathema; Michael R Jacobs; Thomas J Walsh; Robert A Bonomo; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

3.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079

Review 4.  Carbapenemase-Producing Organisms: A Global Scourge.

Authors:  Robert A Bonomo; Eileen M Burd; John Conly; Brandi M Limbago; Laurent Poirel; Julie A Segre; Lars F Westblade
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

Review 5.  OXA-48-like carbapenemases producing Enterobacteriaceae in different niches.

Authors:  Assia Mairi; Alix Pantel; Albert Sotto; Jean-Philippe Lavigne; Aziz Touati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-10-08       Impact factor: 3.267

6.  wzi Gene sequencing, a rapid method for determination of capsular type for Klebsiella strains.

Authors:  Sylvain Brisse; Virginie Passet; Anita Björk Haugaard; Anamaria Babosan; Najiby Kassis-Chikhani; Carsten Struve; Dominique Decré
Journal:  J Clin Microbiol       Date:  2013-10-02       Impact factor: 5.948

Review 7.  New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors:  Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191
  7 in total
  12 in total

Review 1.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain.

Authors:  Marta Hernández-García; María García-Castillo; Patricia Ruiz-Garbajosa; Germán Bou; María Siller-Ruiz; Cristina Pitart; Irene Gracia-Ahufinger; Xavier Mulet; Álvaro Pascual; Nuria Tormo; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2022-01-10       Impact factor: 5.938

3.  Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.

Authors:  Islam M Ghazi; Wasim S El Nekidy; Regan Asay; Paul Fingmori; Anthony Knarr; Mina Awad
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

Review 4.  Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.

Authors:  Maxwell J Lasko; David P Nicolau
Journal:  Curr Infect Dis Rep       Date:  2020-02-07       Impact factor: 3.725

Review 5.  Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales.

Authors:  Xing Tan; Hwan Seung Kim; Kimberly Baugh; Yanqin Huang; Neeraja Kadiyala; Marisol Wences; Nidhi Singh; Eric Wenzler; Zackery P Bulman
Journal:  Infect Drug Resist       Date:  2021-01-18       Impact factor: 4.003

Review 6.  Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.

Authors:  Young-A Heo
Journal:  Drugs       Date:  2021-02-25       Impact factor: 9.546

Review 7.  A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Authors:  Toni A Campanella; Jason C Gallagher
Journal:  Infect Drug Resist       Date:  2020-11-25       Impact factor: 4.003

Review 8.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

Review 9.  Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections.

Authors:  Corneliu Ovidiu Vrancianu; Elena Georgiana Dobre; Irina Gheorghe; Ilda Barbu; Roxana Elena Cristian; Mariana Carmen Chifiriuc
Journal:  Microorganisms       Date:  2021-03-31

Review 10.  Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Elena-Georgiana Dobre; Ilda Czobor Barbu; Roxana Elena Cristian; Marcela Popa; Sang Hee Lee; Carmen Limban; Ilinca Margareta Vlad; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.